Compositions and methods related to ebolavirus vaccines
AssigneeThe Scripps Research Institute
InventorsLinling He, Jiang Zhu, Anshul Chaudhary, Ian Wilson
Life of this patent
Estimating the term…
Abstract
The present invention provides novel engineered Ebolavirus GP proteins and polypeptides, as well as scaffolded vaccine compositions that display the engineered proteins. The invention also provides methods of using such engineered Ebolavirus GP proteins and vaccine compositions in various therapeutic applications, e.g., for preventing or treating Ebolavirus infections.
Claims29
An engineered Ebolavirus glycoprotein (GP) protein, comprising (a) substitution of residue W615 in heptad repeat 2 (HR2) with residue L, A, V, I or F, and (b) one or more proline substitutions in heptad repeat 1 C segment (HR1C);
- wherein the amino acid numbering is based on Zaire Ebolavirus GP sequence with UniProt ID Q05320 (SEQ ID NO:1).
An engineered Ebolavirus glycoprotein (GP) protein, comprising:
- (a) a truncated soluble GP of an Ebolavirus that has the mucin-like domain (MLD) deleted from the GP1 subunit and the membrane proximal external region (MPER) deleted from the GP2 subunit, and (b) substitution of residue W615 in heptad repeat 2 (HR2) with residue L, A, V, I or F;
- wherein the amino acid numbering is based on Zaire Ebolavirus GP sequence corresponding to UniProt ID Q05320 (SEQ ID NO:1).
Dependencies are inferred from the claim text.